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Highlights  
- Biophysical models have reached a level of sophistication whereby they are able to 
simulate outcomes using the principal proteins that  determine acute electrophysiological 
drug responses 
- Multi-scale simulations allow the effects, characterised at the protein scale, of drugs to be 
interpreted in the context of the whole heart. 
- Despite their inbuilt assumptions and inherent limitations biophysical models provide a 
rational framework for integrating disparate pharmacological measurements.  
Abstract 
Pharmacology is characterised by linking compound molecular properties to cellular and organ scale 
therapeutic and toxic outcomes. Biophysical modelling allow data from these disparate sources to 
be integrated and interpreted based on known physiology and physical constraints of the biological 
systems of interest. Here we describe the recent use of biophysical models to simulate therapeutic 
and adverse drug effects on the heart and how this provides a new framework for data integration 
and identifying drug mechanisms.  
Introduction 
Large genomic1, 2, compound property3, 4 and pathway5, 6 data bases are increasingly utilised to 
better understand and predict the effectiveness and toxicity of novel compounds7, 8. Combining 
information across multiple data sets further enhances the capacity to predict the effect of a drug on 
patients. Central to this approach is the mapping of information of similarity between records which 
requires developing novel methods9-11. These methods will have the capacity to identify compounds 
that cause toxic or therapeutic outcomes by integration of their molecular actions. 
The way such data have been used to date has been to focus on individual measures of molecular 
effect (e.g., IC50) and extrapolate a whole organ outcome using semi-empirical ‘truths’, such as a 
submicromolar affinity for a particular ion current that will, have a certain risk (liability) for causing a 
certain adverse outcome. This is somewhat limited and, as noted below, can be misleading. While 
some attempt has been made to combine multiple variables using probabilistic models to predict 
outcome, this approach makes little or no use of the known physiology and physics of the underlying 
biological system (integration and interaction). Here we discuss how biophysical models provide a 
rational framework for data processing and interpretation, as depicted in Figure 1.  
Biophysical modelling approaches, including physiome based12, systems biology13, quantitative 
systems pharmacology14 and physiologically based pharmacokinetic modelling (PKPD)15, 16, provide a 
framework that encodes quantitative information about physiology and anatomy in accordance with 
physical principals to generate outcomes that can be judged in terms of how well they mimic the 
real situation12, 17. When components of a model are set sufficiently well that they not only allow 
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good recapitulation of the basal state but also recapitulate the effects of well-characterised drugs, 
this permits inference about the relative role of individual components of the model (i.e., relative 
contribution of a current and its inhibition to the whole organ effect of a drug). Modeling has 
therefore increasingly moved from understanding physiology and pathology to interpreting the 
effects of pharmacological agents18, 19 and medical interventions17, 20. Here we discuss the recent 
advances that have led to models being used to interpret drug effects.  
Where can computational models add value to conventional pharmacology?  
The complexity of drug effects exists at several levels. First, an effect on a single molecular target 
(e.g., the sodium pump) can have multiple short- and long-term outcomes. Second, most drugs lack 
molecular target selectivity, meaning that a range of targets require to be incorporated into 
modelling. The latter introduces a need for quite accurate information on relative affinities of the 
drug for different molecular targets, and efficacy (in the classical pharmacological sense – the ability 
to achieve a response equal to that of a full agonist). Finally, gaps in knowledge and inconsistencies 
in reported quantitative vales (for IC50s etc) can render drug characterisation across multiple 
laboratories a prolonged and lugubrious process, in some cases spanning decades. Underpinning this 
are mundane issues such as the changes in technology, methodology, preparations and preferred 
species that occur over time. Consequently interpreting multiple experimental data sets and the 
disparate hypothesis these generate can be very challenging. Nevertheless, biophysical models 
provide a framework to formally rationalise how disparate data can be interpreted and combined, 
accounting for different doses, disparities between species and experimental approaches. The 
alternative is an informal approach to analysis, whereby assumptions (e.g., about the role of a drug 
action on IKs, in mediating changes in action potential duration (APD)) are made from isolated data 
sets (e.g., patch clamp data) and extrapolated to predict what the drug may do in a whole heart. This 
approach, which is a form of reductionism in reverse (‘extrapolationism’?) has often failed and 
indeed the role of IKs block in mediating reverse rate-dependence, an issue contested 20 years ago 
by Gintant21 and Sanguinetti and Jurkiewicz22 remained contested even quite recently23.  Integrative 
modelling using more complex approaches is logically likely to be more yielding simply because it 
incorporates more than one variable.  
Thus, performing a factorial or sensitivity analysis on a computational model24, 25, written with 
consideration of data on all known variables of potential relevance, can be expected to identify how 
important each variable is in determining the whole organ drug effect and in turn identify the 
relative importance of each experimental observation. This approach can then be used to identify 
which drug target is principally responsible for the therapeutic or toxic effects of the drug and can be 
used to refine the molecular design, dosage or administration.  
Multi-scale biophysical models can also evaluate the relative importance of available data sets26. This 
requires that the model first be validated (in as much as it should consistently predict whole organ 
effects of drugs of differing molecular specificity and selectivity). A validated model that cannot 
recapitulate whole organ effects of a novel drug based on a reported data set of values of its IC50s 
is, in effect, identifying that the data set has dubious provenance. A model that is largely validated 
but that has predictive flaws and does not incorporate IC50 values for all known potentially relevant 
variables (e.g., chloride-bicarbonate exchange, a rather obscure molecular target) is nevertheless of 
value because it can potentially be used to model whether incorporation of drug effects on the 
orphan target may change function, informing a decision about whether a search for a drug that has 
such effects may be justified. This can also be particularly important when seeking to identify 
unknown off target effects of a drug with a well characterised effect on the whole heart. In other 
words, modelling can operate in a forward direction (from molecular targets) or a backward 
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direction (from the whole organ) with best fit outcomes used in a reiterative way to obtain the best 
description of the biological process or the pharmacological specificity and selectivity of a drug. 
To illustrate these points, the cardiac myocyte is the standard entry level preparation for elaborating 
IC50 values for drug effects on ion channels, pumps, antiporters, symporters, and increasingly 
integrated readouts such as calcium transients and cell mechanics responses. The inability of an 
effect on a known molecular target for a drug to recapitulate cellular scale outcomes (as they 
emerge – data values and their provenance improve with time) implies that actions on at least one 
other molecular target are necessary to account for the cellular scale outcome, and modelling can be 
used to identify which pump, channel etc., potentially represent the unknown relevant molecular 
targets for the drug, using recapitulation of known drug-induced changes in cellular function as the 
template.  
Cardiac models have been created to simulate every scale of function from the whole heart down to 
protein (drug molecular target) function27-29. The heart is intrinsically regulated across scales with 
tissue scale electrical properties, including anisotropic conductivity and wave curvature altering 
cellular scale electrophysiology and tissue properties, with shape and boundary conditions of the 
heart all featuring. This illustrates how reductionist model-free extrapolation of drug molecular 
effects to the whole organ is generally futile, and akin to an attempt to recapitulate a human foot 
based only on measurements of the toe. Despite this self-evident truth, there can be concerns about  
modelling, along the lines that when a model fails to predict exactly the whole organ outcome the 
model must be flawed and hence of no value, and also along the lines that when a drug’s wet 
biology IC50 data values are inconsistent then any modelling is futile. The latter fails to acknowledge 
the real world solution; investigators who select to not attempt formal modelling have no option 
other than to pick and choose what they regard as relevant and important in a model-free fashion 
that is, almost by definition, context free and valueless. When the research goal is to identify the 
mechanism of toxicity of a widely used drug, best in class, for which there is no therapeutic 
alternative and yet there is toxicity of uncertain cause, it becomes highly inappropriate to not 
attempt to evolve a model of the toxicity, regardless of the provenance of the wet biology IC50 
values used to elaborate the model. Simulating the consequences of drug effects on molecular 
targets in the context of the whole organ increases our capacity to predict how novel drugs will 
affect different pathways and whole organ function.   
How are biophysical models currently being applied to study toxicity data? 
A common adverse drug reaction (ADR) occurs when drugs interact with cardiac ionic channels. 
Resultant alterations in action potential (AP) propagation, with effects manifested and detected in 
the electrocardiogram (ECG),  may lead to cardiac arrhythmias (‘proarrhythmia’) with torsades de 
pointes (TdP) a potentially life-threatening example. Due to a statistical association between risk of 
TdP and prolongation of the QT interval in the ECG, an effect known to result from prolongation of 
ventricular APD, several regulatory agencies prohibit the commercialization of drugs that prolong 
APD and/or prolong the QT interval, with greatest emphasis on the latter (especially the human QT 
interval). The molecular basis for QT prolongation is, however complex, with a strong statistical link 
to block of the delayed rectifying potassium current (IKr) but with enormous nuance (verapamil is a 
potent IKr blocker but owing to molecular target promiscuity has no effect on QT interval and no TdP 
liability). It is crucial to identify TdP liability early in drug discovery so as to exclude the toxic 
pharmacophore as early as possible to facilitate selection and prioritization of compounds in the 
process of drug development. However, although there is some insight into the molecular target 
specificity and selectivity necessary for generating or avoiding a TdP liability (e.g., see above), the 
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nuance remains intractable and this has generated yet another recent multidisciplinary initiative to 
find a better sequence of investigations at the protein and cell scale to generate an ‘integrated’ 
process for ensuring drugs are not discarded needlessly (at patch clamp stage) for a suspected TdP 
liability that does not exist. This is the Comprehensive in Vitro Proarrhythmia Assay (CiPA) 
initiative30. The most important part of CiPA will be the modeling that is intended to be undertaken 
once a large set of reliable and systematically derived ‘wet’ lab data (IC50s etc) has been assembled 
for a broad range of drugs.  
 
In the existing approach to TdP liability testing, there has been a somewhat myopic focus on IKr. This 
current plays a major role in cardiac repolarization and is generated by an ion channel, Kir, encoded 
by the human ether-à-go-go related gene (hERG), resulting in the concept of ‘hERG screening’, a 
shorthand for measurement of block of IKr, or binding to Kir. The value of IKr screening is that there 
are very few (if any) false negatives (drugs that have no effect on IKr yet cause TdP). However, as 
noted above, there is an issue with false positives. Thus, this focus on a single ion channel renders 
‘hERG screening’ a low sensitivity approach.  The potential value of biophysical models, see Figure 2, 
is therefore of great interest in the TdP field, as exemplified by the CiPA initiative.  
 
In drug discovery, the expectation is that biophysical models will allow insights and predictions to be 
made using data acquired at the early high-throughput stages of investigation, with rapid 
interchange between emerging data and modeling, with the former populating the input for the 
latter, and the latter informing the direction of the former. Measurements of drug absorption and 
metabolism can be used to predict drug tissue concentrations16. Voltage clamp experiments, 
performed as part of multiple ion channel screening, using cell lines, generate IC50 data that can be 
readily incorporated into computational models of varying levels of complexity.  These models 
provide a unique method to link drug interactions at the molecular target level to predict altered 
function at increasingly integrated levels of function, from ionic currents to action potentials31, 32, 
conduction (reentry) 33-35 and global heart rhythm itself (the ECG)36-39. This provides a quantitative 
link between pre-clinical protein kinetics assays and organ clinical indices.  
 
What are the future opportunities for biophysical models? 
The hope and expectation is that in silico testing will play a central role in the regulatory aspect of 
TdP liability testing (and perhaps other types of testing) in the near future. The integration of direct 
drug-molecular target interaction data is a potentially powerful method for modelling acute drug 
effects; however, it offers only limited potential when it comes to studying chronic cardiotoxicity. 
Although direct drug-molecular target interaction data can be used to investigate events that serve 
as triggers of toxicity, it cannot capture the long-term effects that persist after the drugs have been 
eliminated from the system (adaptive changes and genomic responses).  
Chronic cardiotoxicity is often a progressive process that is commonly associated with drug induced 
damage and alterations in gene expression40. A typical example is antineoplastic anthracycline 
cardiotoxicity that can lead to congestive heart failure years or even decades after the termination 
of the treatment. Although it is known that anthracycline use can be associated with mitochondrial 
dysfunction, oxidative stress and alterations in gene expression41, the precise mechanism(s) resulting 
in its cardiotoxicity are still not fully elucidated. 
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Although biophysical models have recently been elaborated to allow study of progressive 
mitochondrial dysfunction and chronic cardiotoxicity42, advancements in large-scale quantitative 
proteomics43 generate unprecedented additional opportunities for the application of such models in 
this field. Proteomics databases with consecutive measurements can be used to regulate and fine-
tune the abundances of all proteins and enzymes represented in the models at different stages. This 
may allow the development of novel tools for the systematic identification of pathways and 
biomarkers for the characterization of progressive pathologically and drug induced heart conditions. 
Summary 
Biophysical cardiac models have provided a framework for furthering our understanding of cardiac 
physiology and pathology. These models offer the same opportunity for pharmacology to 
understand the integrative therapeutic and toxic effects of drugs on the heart. 
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Figure 1: Schematic depiction of the integration of multiple binding assay measurements (left panel) 
into cellular and organ scale biophysical models (central panel). Where cellular biophysical models 
represent the molecular regulation of cellular physiology and can be integrated into organ scale 
models. These models can then predict pharmacologically induced changes in emergent cellular (e.g. 
action potential) and whole organ (e.g. pressure-volume loop) function.  
 
 
Figure 2: Schematic of cell models showing the development of increasing complex models from 
single channel ligand based approaches44 through to integrated 345, 519, 46 and 647 channel 
approaches for predicting Torsade de Point risk.  
 
